Trial Profile

An open-label investigator-led study being conducted in pediatric subjects Netherton Syndrome

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs QRX 003 (Primary)
Indications Netherton Syndrome
Focus Therapeutic Use

Most Recent Events

26 Mar 2026 According to a Quoin Pharmaceuticals media release, the company anticipates reporting topline data in the second half of 2026.
28 Oct 2025 According to a Quoin Pharmaceuticals media release, all three subjects will undergo twice-daily, whole-body application of QRX003 for an initial twelve-week period, after which they will continue treatment in a long-term extension protocol until regulatory approval is secured. Two subjects are based in Austria, and the third resides in Ireland.
28 Oct 2025 Results published in a Quoin Pharmaceuticals media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com